Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) released its quarterly earnings data on Thursday, January, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.14. The biotechnology company earned $1.13 million during the quarter, compared to analysts' expectations of $1.10 million. Advaxis had a negative return on equity of 187.23% and a negative net margin of 1,096.88%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
3 analysts have issued 12 month price objectives for Advaxis' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Advaxis' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
Has Advaxis been receiving favorable news coverage?
News headlines about ADXS stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Advaxis earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Sierra Oncology (SRRA), DURECT (DRRX), Apricus Biosciences (APRI), Catalyst Biosciences (CBIO), ASLAN PHARMACEU/ADR (ASLN), Humanigen (HGEN), OASMIA PHARMACE/ADR (OASM), Vernalis (VNLPY), Chimerix (CMRX), vTv Therapeutics (VTVT), Chiasma (CHMA), Evofem Biosciences (EVFM), Zynerba Pharmaceuticals (ZYNE), Cumberland Pharmaceuticals (CPIX) and Teligent (TLGT).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin, Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Noelle Heber, Sr. Director of Corp. Communications & Gov. Affairs
Who are Advaxis' major shareholders?
Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include CVI Holdings LLC (3.15%), BlackRock Inc. (2.07%), D. E. Shaw & Co. Inc. (0.58%), Two Sigma Investments LP (0.53%) and Virtu Financial LLC (0.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis.
Which institutional investors are selling Advaxis stock?
Which institutional investors are buying Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.40.
How big of a company is Advaxis?
Advaxis has a market capitalization of $27.88 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Advaxis employs 58 workers across the globe.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
